Guggul (Expanded) for Joint Health

Research suggests that guggul and its related preparations show consistent anti-inflammatory and anti-arthritic properties across a range of study types, including in vitro and animal models, network pharmacology analyses, traditional use reviews, and at least one clinical randomized controlled trial. Studies indicate that active compounds in guggulipid, particularly guggulsterones, appear to modulate key inflammatory pathways such as COX-2 and NFκB, which are implicated in conditions like rheumatoid arthritis, osteoarthritis, and gout. The body of evidence is largely supportive in direction, though much of it comes from preclinical models, narrative reviews, and traditional pharmacological surveys rather than large, well-controlled human trials, which limits the strength of conclusions that can be drawn. The 2025 RCT involving Boswellia serrata, a related guggul preparation, provides some clinical support for joint function improvements, but more rigorous human trials across the broader guggul category would be needed to establish the full scope of its effects in joint health applications.